Antibiotic Combination for Healthcare-Associated Pneumonia After Recent COVID-19 Infection

Initial Empiric Therapy Recommendations

The American College of Physicians recommends a β-lactam (such as piperacillin/tazobactam) plus either a macrolide or a fluoroquinolone for healthcare-associated pneumonia after recent COVID-19 infection, with additional coverage for multidrug-resistant pathogens in critically ill patients 1, 2
For non-critically ill patients, the Infectious Diseases Society of America recommends β-lactam (ampicillin-sulbactam, ceftriaxone, or cefotaxime) plus either a macrolide (azithromycin or clarithromycin) or doxycycline 3, 4
Respiratory fluoroquinolone (levofloxacin or moxifloxacin) as monotherapy is an alternative option for non-critically ill patients 3

The bacterial pathogens in COVID-19-associated pneumonia are likely the same as in other pneumonias, including Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus 3, 4
For HCAP specifically, coverage should include potential multidrug-resistant pathogens, particularly Pseudomonas aeruginosa and MRSA in patients with specific risk factors 5

The American College of Chest Physicians recommends obtaining comprehensive microbiologic workup before administering empirical antibiotics to facilitate appropriate adjustment or de-escalation 1
Blood and sputum cultures should be collected before initiating antibiotics, especially when expanded coverage for multidrug-resistant pathogens is planned 5
Consider syndromic diagnostic testing (multiplex PCR) using specimens from endotracheal tube or bronchoalveolar lavage in critically ill patients to guide therapy 1

If culture results are negative and the patient is improving, narrow or discontinue expanded antibiotic therapy within 48 hours 5, 2
A 5-day course of antibiotic therapy is adequate for most patients with pneumonia, including those with COVID-19 6, 2
Use procalcitonin levels to guide early discontinuation of antibiotics, especially in patients with less severe disease 6

Not all COVID-19 patients require antibiotics; radiographic abnormalities may be due to the viral infection alone 3
Procalcitonin may be elevated in COVID-19 due to inflammatory activation rather than bacterial co-infection 6
Antibiotics should not be routinely prescribed for COVID-19 patients receiving immunomodulatory agents without evidence of bacterial infection 1